Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 327 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizophrenia and Related Disorders Clear all
Recruiting Not applicable Interventional

A Novel Peer-Delivered Recovery-Focused Suicide Prevention Intervention for Veterans With Serious Mental Illness

NCT05537376
View directory record Official record
Conditions
Psychotic Disorders, Bipolar Disorders, Suicidal Ideation, Suicide, Attempted
Interventions
SUicide Prevention by Peers Offering Recovery Tactics
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 21, 2026, 11:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Nicotine on Areas of Impaired and Preserved Functioning in Schizophrenia

NCT01034085
View directory record Official record
Conditions
Nicotine Dependence, Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

Risperidone and Desipramine in Alcohol Use and Schizophrenia

NCT01411085
View directory record Official record
Conditions
Schizophrenia, Alcoholism, Dual Diagnosis
Interventions
Risperidone + Desipramine
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Worcester, Massachusetts • Grand Rapids, Michigan • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Not applicable Interventional

Can Neural Network Instability in Schizophrenia be Improved With a Very Low Carbohydrate Ketogenic Diet?

NCT05268809
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder
Interventions
Ketogenic diet
Other
Lead sponsor
Northern California Institute of Research and Education
Other
Eligibility
18 Years to 65 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 21, 2026, 11:25 AM EDT
Not listed No phase listed Observational

Schizophrenia and PTSD Project: Health, Interventions, and Risk/Resilience Evaluation(SAPPHIRE Study)

NCT00560677
View directory record Official record
Conditions
Schizophrenia, PTSD
Interventions
Not listed
Lead sponsor
Durham VA Medical Center
Federal
Eligibility
18 Years to 72 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 1 Interventional

Movement Disorders Caused by Antipsychotic Drugs in Older Patients

NCT00255879
View directory record Official record
Conditions
Dyskinesia, Drug-Induced
Interventions
Quetiapine, Risperidone, Olanzapine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia

NCT00136760
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder
Interventions
Bupropion, Contingent reinforcement plus placebo, non-contingent reinforcement plus bupropion, Non-contingent reinforcement plus placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 2 Interventional

Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder in Individuals With Severe Mental Illness

NCT00078741
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Schizophrenia
Interventions
Cognitive Behavioral Therapy (CBT)
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Charleston, South Carolina • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2015 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 1 Interventional

Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder

NCT03872596
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Seroquel IR 300mg, Seroquel IR 25mg, Quetiapine Formulation A 300mg, Quetiapine Formulation B 300mg, Quetiapine Formulation 25mg
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 4 Interventional Results available

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

NCT06041646
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing Igalmi
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Little Rock, Arkansas • Rogers, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Not applicable Interventional Results available

Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone

NCT00538642
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
ziprasidone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of ∆-9-THC and Naloxone in Humans

NCT01591629
View directory record Official record
Conditions
Healthy
Interventions
Naloxone, Delta-9-THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Integrated Care (IC) Models for Patient-Centered Outcomes

NCT03451630
View directory record Official record
Conditions
Diabetes, Asthma, Chronic Obstructive Pulmonary Disease, Hypertension, Anxiety, Atrial Fibrillation, Congestive Heart Failure, Depression, Bipolar Disorder, Schizophrenia
Interventions
High-Touch, High-Tech, Optimal Discharge Planning
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
1,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Not applicable Interventional

Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness

NCT02421965
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
Interventions
FOCUS (Smartphone Application), WRAP (Wellness Recovery Action Planning)
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Pediatric Open-Label Extension Study

NCT01914393
View directory record Official record
Conditions
Schizophrenia, Autism, Bipolar Depression
Interventions
Lurasidone 20, 40, 60, 80 mg, flexibly dosed
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
35
States / cities
Dothan, Alabama • Downey, California • San Francisco, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone

NCT02576912
View directory record Official record
Conditions
Healthy
Interventions
Active Delta-9-THC, Active Pregnenolone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 6, 2023 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Abilify Therapy for Reducing Comorbid Substance Abuse

NCT00208169
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Anxiety Disorders, Substance Abuse
Interventions
Aripiprazole
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 23, 2007 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 1 Interventional

Benefits Management for People With Psychiatric Disabilities

NCT01329393
View directory record Official record
Conditions
Dual Diagnosis, Schizophrenia, Bipolar Disorder
Interventions
Benefits Management, Illness Management and Recovery
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 29, 2020 · Synced Jul 21, 2026, 11:25 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

FAAH Availability in Psychiatric Disorders: A PET Study

NCT04404712
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Alcohol Use Disorder, Psychosis
Interventions
[11C]MK-3168
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jul 21, 2026, 11:25 AM EDT
Recruiting Not applicable Interventional

A Mental Health Services Engagement Program for Racial and Ethnic Minority Young Adults

NCT06508450
View directory record Official record
Conditions
Psychosis, Bipolar and Related Disorders, Depressive Disorder
Interventions
Just Do You, Component A, Component B, Component C
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years to 34 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Not applicable Interventional Results available

Circuitry-Guided Smoking Cessation in Schizophrenia

NCT03281629
View directory record Official record
Conditions
Smoking Cessation, Nicotine Addiction, Schizophrenia
Interventions
Active TMS stimulation, Sham TMS stimulation
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Jul 21, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

NCT03325556
View directory record Official record
Conditions
Dementia-related Psychosis
Interventions
Placebo, Pimavanserin 34 mg, Pimavanserin 20 mg
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Costa Mesa, California • Fullerton, California • Aventura, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Jul 21, 2026, 11:25 AM EDT
Completed No phase listed Observational

Factors Association With Poor Physical Function in Older Adults With Schizophrenia

NCT01092598
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Jul 21, 2026, 11:25 AM EDT